NCT06463834View on ClinicalTrials.gov

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

March 19, 2025

Study Completion Date

March 19, 2028

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab

"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"

Trial Locations (1)

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV